» Articles » PMID: 12959188

Ovarian Cancer Screening

Overview
Specialties Hematology
Oncology
Date 2003 Sep 10
PMID 12959188
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

In an ongoing effort to design an efficacious, cost-effective ovarian cancer screening method, the existing tests, CA 125 and transvaginal sonography, are being optimized and combined in a multimodal strategy, and new promising serum markers, such as mesothelin and HE4, are being developed and evaluated. Detection has been found to improve when multiple serum markers are used in a longitudinal logarithm. The parametric empirical Bayes approach improves screening algorithms by capturing the stability of markers over time in a heterogeneous population. It also has relatively simple extensions to multiple markers. The evaluation of markers increasingly accounts for characteristics of a woman that may affect her marker levels and accounts for the cancer's characteristics, histology, and grade. Receiver operating characteristic curves are helpful for evaluation because they relate a marker's sensitivity to the specificity at which it operates. Large, well-designed randomized controlled trials are under way to gauge the performance of existing screening methods.

Citing Articles

The diagnostic performance of the Mindray system in detecting CA125 and HE4 for patients with ovarian cancer.

Feng P, Chen T, Wischhusen J, Ladbury C, Vargas-Hernandez V, Xiong Y Transl Cancer Res. 2024; 13(8):4474-4484.

PMID: 39262481 PMC: 11385533. DOI: 10.21037/tcr-24-1107.


Comparison of the diagnostic efficacy of systemic inflammatory indicators in the early diagnosis of ovarian cancer.

Song L, Wu Q, Bai S, Zhao J, Qi J, Zhang J Front Oncol. 2024; 14:1381268.

PMID: 39015497 PMC: 11250249. DOI: 10.3389/fonc.2024.1381268.


Demons-Meigs syndrome caused by a giant ovarian fibroma: A case report.

Guelzim Y, Bennasser A, Marrakchi S, Houssaini A, Idoubba S, Boujida I Radiol Case Rep. 2024; 19(7):2585-2589.

PMID: 38645957 PMC: 11026527. DOI: 10.1016/j.radcr.2024.03.016.


Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives.

Zhang H, Wang L, Wu H Front Oncol. 2024; 13:1276085.

PMID: 38169730 PMC: 10758434. DOI: 10.3389/fonc.2023.1276085.


Survival prognosis model for elderly women with epithelial ovarian cancer based on the SEER database.

Zhou Y, Wang A, Sun X, Zhang R, Zhao L Front Oncol. 2023; 13:1257615.

PMID: 37841445 PMC: 10570503. DOI: 10.3389/fonc.2023.1257615.